WAVE LIFE SCIENCES LTD. Increase (Decrease) in Other Noncurrent Liabilities
WAVE LIFE SCIENCES LTD. (WVE) reported Increase (Decrease) in Other Noncurrent Liabilities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-02-26
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for the quarter ending 2023-12-31 was $0.00.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for the quarter ending 2022-06-30 was -$868.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for the quarter ending 2022-03-31 was $868.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for the quarter ending 2021-12-31 was -$1.01M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $0.00.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$190.00K, a 200.00% decline from fiscal 2022.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $190.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in other noncurrent liabilities for fiscal 2021 was -$474.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$190.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | -$190.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $190.00K 10-K · filed 2025-03-04 | |||
| 2022-06-30 | -$868.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | -$1.01M derived: sum of 3 quarters · filed 2023-05-03 | -$339.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-03-31 | $868.00K 10-Q · filed 2023-05-03 | -$146.00K derived: sum of 2 quarters · filed 2023-05-03 | $529.00K derived: sum of 3 quarters · filed 2023-05-03 | $461.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$339.00K derived: sum of 2 quarters · filed 2023-03-23 | -$407.00K derived: sum of 3 quarters · filed 2023-03-23 | -$474.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $675.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $607.00K derived: sum of 2 quarters · filed 2022-11-10 | $540.00K 10-Q · filed 2022-11-10 | -$406.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$68.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$135.00K 10-Q · filed 2022-08-11 | -$1.08M derived: sum of 3 quarters · filed 2022-08-11 | -$1.18M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$67.00K 10-Q · filed 2022-05-12 | -$1.01M derived: sum of 2 quarters · filed 2022-05-12 | -$1.11M derived: sum of 3 quarters · filed 2022-05-12 | -$1.21M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$1.05M derived: sum of 2 quarters · filed 2022-03-03 | -$1.15M derived: sum of 3 quarters · filed 2022-03-03 | -$1.25M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$201.00K derived: sum of 2 quarters · filed 2021-11-10 | -$301.00K 10-Q · filed 2021-11-10 | -$373.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$201.00K 10-Q · filed 2021-08-05 | -$273.00K derived: sum of 3 quarters · filed 2021-08-05 | -$377.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$100.00K 10-Q · filed 2021-05-13 | -$172.00K derived: sum of 2 quarters · filed 2021-05-13 | -$276.00K derived: sum of 3 quarters · filed 2021-05-13 | -$418.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$176.00K derived: sum of 2 quarters · filed 2021-03-04 | -$318.00K derived: sum of 3 quarters · filed 2021-03-04 | -$421.00K 10-K · filed 2021-03-04 |
| 2019-09-30 | -$104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$246.00K derived: sum of 2 quarters · filed 2020-11-09 | -$349.00K 10-Q · filed 2020-11-09 | $298.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$245.00K 10-Q · filed 2020-08-10 | $402.00K derived: sum of 3 quarters · filed 2020-08-10 | $364.00K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$103.00K 10-Q · filed 2020-05-11 | $544.00K derived: sum of 2 quarters · filed 2020-05-11 | $506.00K derived: sum of 3 quarters · filed 2020-05-11 | $434.00K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $609.00K derived: sum of 2 quarters · filed 2020-03-02 | $537.00K derived: sum of 3 quarters · filed 2020-03-02 | $523.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$110.00K derived: sum of 2 quarters · filed 2019-11-05 | -$124.00K 10-Q · filed 2019-11-05 | $474.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$86.00K 10-Q · filed 2019-08-06 | $512.00K derived: sum of 3 quarters · filed 2020-03-02 | -$537.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$14.00K 10-Q · filed 2019-05-10 | $584.00K derived: sum of 2 quarters · filed 2020-03-02 | -$465.00K derived: sum of 3 quarters · filed 2020-03-02 | -$450.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$451.00K derived: sum of 2 quarters · filed 2020-03-02 | -$436.00K derived: sum of 3 quarters · filed 2020-03-02 | $823.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$1.03M derived: sum of 2 quarters · filed 2018-11-09 | $225.00K 10-Q · filed 2018-11-09 | $1.10M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.27M 10-Q · filed 2018-08-09 | $2.15M derived: sum of 3 quarters · filed 2019-03-01 | $2.15M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $1.26M 10-Q · filed 2018-05-09 | $2.14M derived: sum of 2 quarters · filed 2019-03-01 | $2.13M derived: sum of 3 quarters · filed 2019-03-01 | $2.13M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $877.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $873.00K derived: sum of 2 quarters · filed 2019-03-01 | $869.00K derived: sum of 3 quarters · filed 2019-03-01 | $864.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$8.00K derived: sum of 2 quarters · filed 2017-11-09 | -$13.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$9.00K 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | -$5.00K 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $38.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |